Kathryn Vanderlaag

Kathryn joined Notable Labs in 2020 and is currently leading the R&D team. She has 18 years of cancer research experience, including 13 in the pharmaceutical industry. Prior to joining Notable, Kathryn led a team of scientists in IO Discovery at Bristol Myers Squibb in both the preclinical and early clinical phase programs. Previously, she held roles of increasing responsibility at Health Canada, Schering Plough (acquired by Merck) and Novartis.

Kathryn received her bachelor’s from the University of Guelph in Ontario in Biomedical Toxicology and her Ph.D. from Texas A&M University in Toxicology, where she studied novel mechanisms of action for anti-cancer compounds identified in cruciferous vegetables.